The development and launch of a new, original drug is a significant event in the life of every pharmaceutical company and an important step forward in the treatment of certain diseases. This is also why original research is of great importance in the implementation of Richter's strategy. Our researchers are committed to working on projects that bring new, innovative therapies to patients worldwide.
original projects in the pipeline
% of revenue spent on R and D
Innovation Grand Prix
"Medicine of the Year" in Hungary
Original research at Richter
The area of our original research is a wide range of neuropsychiatric and neurodegenerative diseases, in which we aim to treat negative, cognitive and positive symptoms related to these disorders. Selecting biological targets associated with diseases is always a major challenge for our researchers, as it is of paramount importance for our future success. Selecting the ideal compound to act on requires dedicated work from our medicinal chemists, biologists, and pharmacologists over a period of 3-5 years. To achieve this goal, we use state-of-the-art technical tools, such as our automated test systems and chemistry software supported by artificial intelligence. If this new compound, which has successfully passed several safety studies, meets all the requirements, it is ready to be used in clinical trials. However, this research phase is not only long but also very costly, so most studies require the involvement of capital-intensive partners.
Unique treatment for CNS disorders
The latest success of our original research activity, also a historical milestone for the Hungarian pharmaceutical industry, is our antipsychotic molecule, cariprazine. The fact that a drug candidate discovered in Hungary by a Hungarian pharmaceutical company and developed with local financial and professional contributions obtained both FDA approval and EU registration is a unique achievement, of which we can justifiably be proud. Unprecedented in the history of the Hungarian pharmaceutical industry, this drug has now exceeded the annual turnover of 1 billion USD and therefore achieved blockbuster status. Today, our product is available in nearly 50 countries and will soon be available on all five continents.